Evidence map›Paper›PMID 32700021›Full record

ArticleEuropean radiology2021

Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps.

Amogh Hiremath, Rakesh Shiradkar, Harri Merisaari, Prateek Prasanna, Otto Ettala, Pekka Taimen, Hannu J Aronen, Peter J Boström, Ivan Jambor, Anant Madabhushi

Open access · greenAbstract read
In one paragraph

Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Amogh HiremathDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA. axh672@case.edu.ORCID http://orcid.org/0000-0001-6937-9141
Rakesh ShiradkarDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Harri MerisaariDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Prateek PrasannaDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Otto EttalaDepartment of Urology, University of Turku and Turku University Hospital, Turku, Finland.
Pekka TaimenInstitute of Biomedicine, Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Hannu J AronenMedical Imaging Centre of Southwest Finland, Turku University Hospital, Turku, Finland.
Peter J BoströmDepartment of Urology, University of Turku and Turku University Hospital, Turku, Finland.
Ivan JamborDepartment of Diagnostic Radiology, University of Turku, Turku, Finland.
Anant MadabhushiDepartment of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
University of Turku · FICase Western Reserve University · USLouis Stokes Cleveland VA Medical Center · USTurku University Hospital · FI

Funding

Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
Pathology Image Informatics Platform for visualization, analysis and managementU24CA199374 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GURCAN, METIN NAFI, MADABHUSHI, ANANT · 2015 to 2019
$2.9M
RadxTools for assessing tumor treatment response on imagingU01CA248226 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI TIWARI, PALLAVI, VISWANATH, SATISH EASWAR · 2020 to 2022
$1.4M
HistoTools: A suite of digital pathology tools for quality control, annotation and dataset identificationU01CA239055 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JANOWCZYK, ANDREW ROBERT, MADABHUSHI, ANANT · 2019 to 2022
$1.0M
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear SlidesR43EB028736 · NIBIB · DIASCOPIC, LLC · PI MADABHUSHI, ANANT, SERIF, CARY · 2019 to 2019
$225k
RadIO: A Novel Radiomics Toolkit to Predict and Characterize Response to Immunotherapy in Stage III Non-Small Cell Lung CancerI01BX004121 · VA · VETERANS HEALTH ADMINISTRATION · PI Anant Madabhushi, Charles J Nock · 2019 to 2026
–
BIOMEDICAL ENGINEERING RESEARCH FACILITIESC06RR012463 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI KUTINA, KENNETH L · 1997 to 1997
–
BLRD VA I01 BX004121BLRD VA IK6 BX006185NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA249992NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U24 CA199374NCRR NIH HHS C06 RR012463NIBIB NIH HHS R43 EB028736
6 · The paper itself

Abstract

objectivesTo evaluate short-term test-retest repeatability of a deep learning architecture (U-Net) in slice- and lesion-level detection and segmentation of clinically significant prostate cancer (csPCa: Gleason grade group > 1) using diffusion-weighted imaging fitted with monoexponential function, ADC

methodsOne hundred twelve patients with prostate cancer (PCa) underwent 2 prostate MRI examinations on the same day. PCa areas were annotated using whole mount prostatectomy sections. Two U-Net-based convolutional neural networks were trained on three different ADC

resultsFor the three ADC

conclusionsFor the three ADC KEY POINTS: • For the three ADC

Indexed as

Deep LearningProstatic NeoplasmsDiffusion Magnetic Resonance ImagingHumansMaleNeural Networks, ComputerReproducibility of ResultsDiffusion MRINeural network modelsProstate cancerTest-retest reliability

Identifiers

PMID32700021
PMCPMC7821380
OpenAlexW3045247358

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.